CO2019003162A2 - Formas cristalinas y salinas de compuestos agonistas de ppar - Google Patents
Formas cristalinas y salinas de compuestos agonistas de pparInfo
- Publication number
- CO2019003162A2 CO2019003162A2 CONC2019/0003162A CO2019003162A CO2019003162A2 CO 2019003162 A2 CO2019003162 A2 CO 2019003162A2 CO 2019003162 A CO2019003162 A CO 2019003162A CO 2019003162 A2 CO2019003162 A2 CO 2019003162A2
- Authority
- CO
- Colombia
- Prior art keywords
- ppar
- crystalline
- agonist compounds
- saline forms
- saline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Esta divulgación se relaciona con formas salinas de compuestos que tienen capacidad para activar PPARδ para su uso en el desarrollo de fármacos y productos farmacológicos, y composiciones y métodos relacionados.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404474P | 2016-10-05 | 2016-10-05 | |
| PCT/US2017/055403 WO2018067860A1 (en) | 2016-10-05 | 2017-10-05 | Crystalline and salt forms of ppar agonist compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019003162A2 true CO2019003162A2 (es) | 2019-05-21 |
Family
ID=60153508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0003162A CO2019003162A2 (es) | 2016-10-05 | 2019-03-29 | Formas cristalinas y salinas de compuestos agonistas de ppar |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US10927094B2 (es) |
| EP (1) | EP3523283B1 (es) |
| JP (1) | JP7017563B2 (es) |
| KR (1) | KR20190057129A (es) |
| CN (1) | CN109843857B (es) |
| AU (1) | AU2017340763B2 (es) |
| BR (1) | BR112019006030A2 (es) |
| CA (1) | CA3036587A1 (es) |
| CO (1) | CO2019003162A2 (es) |
| CY (1) | CY1124655T1 (es) |
| DK (1) | DK3523283T3 (es) |
| ES (1) | ES2887008T3 (es) |
| HR (1) | HRP20211341T1 (es) |
| HU (1) | HUE055678T2 (es) |
| IL (1) | IL265730B (es) |
| JO (1) | JOP20190039B1 (es) |
| LT (1) | LT3523283T (es) |
| MA (1) | MA46460A (es) |
| MX (1) | MX2019003945A (es) |
| MY (1) | MY202008A (es) |
| PH (1) | PH12019500727A1 (es) |
| PL (1) | PL3523283T3 (es) |
| PT (1) | PT3523283T (es) |
| RS (1) | RS62245B1 (es) |
| RU (1) | RU2759724C2 (es) |
| SG (1) | SG11201901995TA (es) |
| SI (1) | SI3523283T1 (es) |
| TW (1) | TWI769182B (es) |
| UA (1) | UA124770C2 (es) |
| WO (1) | WO2018067860A1 (es) |
| ZA (1) | ZA201901744B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2393768T3 (es) | 2005-05-26 | 2012-12-27 | Neuron Systems, Inc | Derivado de quinolina para el tratamiento de enfermedades retinianas |
| PT3359528T (pt) * | 2015-10-07 | 2022-04-07 | Salk Inst Biological Studies | Agonistas de ppar, compostos, composições farmacêuticas e métodos de utilização dos mesmos |
| LT3523283T (lt) | 2016-10-05 | 2021-07-12 | Mitobridge, Inc. | Ppar agonistų junginių kristalinės ir druskos formos |
| EP3694500A4 (en) | 2017-10-10 | 2021-06-30 | Aldeyra Therapeutics, Inc. | TREATMENT OF INFLAMMATORY DISORDERS |
| US20220017475A1 (en) * | 2018-08-06 | 2022-01-20 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| WO2020085393A1 (ja) * | 2018-10-23 | 2020-04-30 | 国立研究開発法人科学技術振興機構 | ＰＰＡＲδ活性化剤 |
| AU2022286415A1 (en) | 2021-06-02 | 2023-12-14 | Astellas Pharma Inc. | Methods of use of ppar agonist compounds and pharmaceutical compositions thereof |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060241157A1 (en) | 2003-01-06 | 2006-10-26 | Conner Scott E | Heterocyclic ppar modulators |
| EP1671633A1 (en) * | 2004-12-17 | 2006-06-21 | Sanofi-Aventis Deutschland GmbH | Use of PPAR agonists for the treatment of congestive heart failure |
| AU2006210503B2 (en) * | 2005-02-03 | 2009-09-03 | Irm Llc | Compounds and compositions as PPAR modulators |
| CN101296892A (zh) * | 2005-09-07 | 2008-10-29 | 普莱希科公司 | Ppar活性化合物 |
| DE102006023336A1 (de) | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole II |
| FR2940289B1 (fr) | 2008-12-23 | 2014-09-12 | Biopharmed | Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas |
| CN102727489A (zh) * | 2012-07-18 | 2012-10-17 | 西南大学 | 5-芳(杂环)亚甲基噻唑烷-2，4-二酮在制备ppar激动剂中的应用 |
| WO2016057658A1 (en) * | 2014-10-08 | 2016-04-14 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| PT3359528T (pt) * | 2015-10-07 | 2022-04-07 | Salk Inst Biological Studies | Agonistas de ppar, compostos, composições farmacêuticas e métodos de utilização dos mesmos |
| KR102430906B1 (ko) * | 2016-04-13 | 2022-08-10 | 미토브리지, 인크. | Ppar 효능제, 화합물, 제약 조성물, 및 그의 사용 방법 |
| MX2019003949A (es) | 2016-10-05 | 2019-06-10 | Mitobridge Inc | Metodos para tratar lesion renal aguda. |
| LT3523283T (lt) | 2016-10-05 | 2021-07-12 | Mitobridge, Inc. | Ppar agonistų junginių kristalinės ir druskos formos |
-
2017
- 2017-10-05 LT LTEPPCT/US2017/055403T patent/LT3523283T/lt unknown
- 2017-10-05 MX MX2019003945A patent/MX2019003945A/es unknown
- 2017-10-05 ES ES17787774T patent/ES2887008T3/es active Active
- 2017-10-05 DK DK17787774.3T patent/DK3523283T3/da active
- 2017-10-05 EP EP17787774.3A patent/EP3523283B1/en active Active
- 2017-10-05 PT PT177877743T patent/PT3523283T/pt unknown
- 2017-10-05 KR KR1020197012668A patent/KR20190057129A/ko not_active Application Discontinuation
- 2017-10-05 MA MA046460A patent/MA46460A/fr unknown
- 2017-10-05 IL IL265730A patent/IL265730B/en unknown
- 2017-10-05 WO PCT/US2017/055403 patent/WO2018067860A1/en active Application Filing
- 2017-10-05 RU RU2019110736A patent/RU2759724C2/ru active
- 2017-10-05 AU AU2017340763A patent/AU2017340763B2/en active Active
- 2017-10-05 UA UAA201903678A patent/UA124770C2/uk unknown
- 2017-10-05 BR BR112019006030A patent/BR112019006030A2/pt active Search and Examination
- 2017-10-05 CN CN201780062034.5A patent/CN109843857B/zh active Active
- 2017-10-05 SI SI201730879T patent/SI3523283T1/sl unknown
- 2017-10-05 JP JP2019518286A patent/JP7017563B2/ja active Active
- 2017-10-05 RS RS20211042A patent/RS62245B1/sr unknown
- 2017-10-05 JO JOP/2019/0039A patent/JOP20190039B1/ar active
- 2017-10-05 SG SG11201901995TA patent/SG11201901995TA/en unknown
- 2017-10-05 MY MYPI2019001560A patent/MY202008A/en unknown
- 2017-10-05 US US16/334,746 patent/US10927094B2/en active Active
- 2017-10-05 CA CA3036587A patent/CA3036587A1/en active Pending
- 2017-10-05 TW TW106134298A patent/TWI769182B/zh active
- 2017-10-05 HU HUE17787774A patent/HUE055678T2/hu unknown
- 2017-10-05 PL PL17787774T patent/PL3523283T3/pl unknown
-
2019
- 2019-03-20 ZA ZA2019/01744A patent/ZA201901744B/en unknown
- 2019-03-29 CO CONC2019/0003162A patent/CO2019003162A2/es unknown
- 2019-04-03 PH PH12019500727A patent/PH12019500727A1/en unknown
-
2021
- 2021-02-19 US US17/179,604 patent/US11530192B2/en active Active
- 2021-08-20 HR HRP20211341TT patent/HRP20211341T1/hr unknown
- 2021-08-31 CY CY20211100775T patent/CY1124655T1/el unknown
-
2022
- 2022-12-16 US US18/082,847 patent/US11912681B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019003162A2 (es) | Formas cristalinas y salinas de compuestos agonistas de ppar | |
| ECSP18094857A (es) | Agonista del receptor de glucocorticoides e inmunoconjugados del mismo | |
| DOP2019000040A (es) | Compuestos de pirrolizina sustituidas y usos de los mismos | |
| CO2017010618A2 (es) | Anticuerpos contra icos | |
| CL2017000902A1 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| UY37036A (es) | Compuestos inhibidores de la quinasa de unión a tank | |
| CL2016002310A1 (es) | Nuevos compuestos bicíclicos. | |
| CR20160500A (es) | Anticuerpos anti-ox40 y métodos de uso | |
| CO2017002160A2 (es) | Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
| DK3190113T3 (da) | Pyrrolopyrimidinforbindelser anvendt som tlr7-agonist | |
| CL2015002855A1 (es) | Derivados de oxopiridina sustituida. | |
| ES2897914T8 (es) | Compuestos que contienen nitrógeno, adecuados para el uso en la producción de poliuretanos | |
| BR112017020491A2 (pt) | composições e métodos para distribuição de agentes de biomacromolécula. | |
| BR112017004209A2 (pt) | derivados de tetrahidronaftaleno que inibem a proteína mcl-1. | |
| CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
| CL2016000009A1 (es) | Tratamiento de rosacea papulopustular con ivermectina. | |
| CL2016001587A1 (es) | Derivado basado en 1,2-naftoquinona y método de preparación del mismo. | |
| CL2015002488A1 (es) | Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen | |
| DOP2018000066A (es) | Compuestos útiles para inhibir ror-gamma-t | |
| CL2016002151A1 (es) | Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico | |
| ES1192835Y (es) | Maquina para el despedregado del terreno | |
| CL2018003143A1 (es) | Compuesto de dihidroisoxazol para uso en el control de piojos de mar | |
| ES1178860Y (es) | Atuendo para facilitar la utilizacion de piedras para chakras | |
| BR112018005299A2 (pt) | 1,1-difeniletilenos substituídos com alquenilfenoxi, processos para sua preparação e seu uso | |
| CL2018002638A1 (es) | Ambrisentan para uso en el tratamiento de insuficiencia renal aguda |